Show simple item record

dc.contributor.author Betschel S
dc.contributor.author Badiou J
dc.contributor.author Binkley K
dc.contributor.author Hebert J
dc.contributor.author Kanani A
dc.contributor.author Keith P
dc.contributor.author Lacuesta G
dc.contributor.author Yang B
dc.contributor.author Aygoren-Pursun E
dc.contributor.author Bernstein J
dc.contributor.author Bork K
dc.contributor.author Caballero T
dc.contributor.author Cicardi M
dc.contributor.author Craig T
dc.contributor.author Farkas, Henriette
dc.contributor.author Longhurst H
dc.contributor.author Zuraw B
dc.contributor.author Boysen H
dc.contributor.author Borici-Mazi R
dc.contributor.author Bowen T
dc.contributor.author Dallas K
dc.contributor.author Dean J
dc.contributor.author Lang-Robertson K
dc.contributor.author Laramee B
dc.contributor.author Leith E
dc.contributor.author Mace S
dc.contributor.author McCusker C
dc.contributor.author Moote B
dc.contributor.author Poon MC
dc.contributor.author Ritchie B
dc.contributor.author Stark D
dc.contributor.author Sussman G
dc.contributor.author Waserman S
dc.date.accessioned 2016-06-28T12:25:53Z
dc.date.available 2016-06-28T12:25:53Z
dc.date.issued 2014
dc.identifier.citation pagination=50 pages 18;journalVolume=10;journalIssueNumber=1;journalTitle=ALLERGY, ASTHMA AND CLINICAL IMMUNOLOGY; hu
dc.identifier.uri http://repo.lib.semmelweis.hu//handle/123456789/2042
dc.identifier.uri doi:10.1186/1710-1492-10-50
dc.description.abstract Hereditary angioedema (HAE) is a disease which is associated with random and often unpredictable attacks of painful swelling typically affecting the extremities, bowel mucosa, genitals, face and upper airway. Attacks are associated with significant functional impairment, decreased Health Related Quality of Life, and mortality in the case of laryngeal attacks. Caring for patients with HAE can be challenging due to the complexity of this disease. The care of patients with HAE in Canada is neither optimal nor uniform across the country. It lags behind other countries where there are more organized models for HAE management, and where additional therapeutic options are licensed and available for use. The objective of this guideline is to provide graded recommendations for the management of patients in Canada with HAE. This includes the treatment of attacks, short-term prophylaxis, long-term prophylaxis, and recommendations for self-administration, individualized therapy, quality of life, and comprehensive care. It is anticipated that by providing this guideline to caregivers, policy makers, patients and their advocates, that there will be an improved understanding of the current recommendations regarding management of HAE and the factors that need to be considered when choosing therapies and treatment plans for individual patients. The primary target users of this guideline are healthcare providers who are managing patients with HAE. Other healthcare providers who may use this guideline are emergency physicians, gastroenterologists, dentists and otolaryngologists, who will encounter patients with HAE and need to be aware of this condition. Hospital administrators, insurers and policy makers may also find this guideline helpful. hu
dc.relation.ispartof urn:issn:1710-1484
dc.title Canadian hereditary angioedema guideline. hu
dc.type Journal Article hu
dc.date.updated 2015-07-28T09:29:12Z
dc.language.rfc3066 en hu
dc.identifier.mtmt 2783802
dc.identifier.pubmed 25352908
dc.contributor.department SE/AOK/K/III. Sz. Belgyógyászati Klinika
dc.contributor.institution Semmelweis Egyetem


Files in this item

xmlui.dri2xhtml.METS-1.0.onlyFromAllowedIP

View/Open

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account